Updated results from Phase 2 clinical trial of perifosine in combination with capecitabine for the treatment of metastatic colon cancer to be presented on Sunday, January 24, 2010
QUÉBEC CITY, Jan. 21 /CNW Telbec/ - Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that updated results from a Phase 2 clinical trial of perifosine (KRX-0401) in combination with capecitabine conducted by its partner and licensee for this compound in the United States, Canada and Mexico, Keryx Biopharmaceuticals Inc. ("Keryx") (Nasdaq: KERX), has been selected for poster presentation at the upcoming American Society of Clinical Oncology ("ASCO") 2010 Gastrointestinal Cancers Symposium, to be held in Orlando, Florida from January 22-24, 2010.
The clinical data to be presented demonstrates the potential safety and efficacy of perifosine in the treatment of patients with metastatic colon cancer. Details on the poster presentation are as follows:
Title: "A Randomized phase II study of perifosine in combination with
capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in
patients with second- or third-line metastatic colon cancer
(mCRC): updated results."
Lead Author: Johanna Bendell, MD
Session Name: General Poster Session C: Cancers of the Colon and
Date: Sunday, January 24, 2010
Presentation Time: 7:00 AM- 8:00 AM; 12:00 NOON-1:00PM
A copy of the above referenced abstract can be viewed online through ASCO's website, www.asco.org.
About Æterna Zentaris Inc.
Æterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at www.aezsinc.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.
SOURCE Aeterna Zentaris Inc.
For further information: For further information: Investor Relations: Dennis Turpin, SVP and CFO, (418) 652-8525 ext. 242, email@example.com; Media Relations: Paul Burroughs, Director of Communications, (418) 652-8525 ext. 406, firstname.lastname@example.org